Artificial Pancreas Devices Systems Market By Device Type (Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems), By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

The artificial pancreas devices systems market was valued at $0.4 billion in 2023, and is projected to reach $0.8 billion by 2033, growing at a CAGR of 8.8% from 2024 to 2033.

Artificial pancreas device is a medical device that mimics the glucose-regulating function of a healthy pancreas, aiming to maintain optimal blood sugar levels. This medical technology is primarily designed to monitor and regulate blood glucose levels in individuals suffering from diabetes, particularly those with type 1 diabetes. These devices aim to restore lost functions, enhance human capabilities, and improve overall quality of life.

The growth of the artificial pancreas devices systems market is majorly driven by alarming increase in global prevalence of diabetes, particularly type 1 diabetes and rise in awareness among patients and healthcare providers about the benefits of artificial pancreas systems. According to the 2021 key findings of IDF Diabetes Atlas 10th edition, approximately 537 million adults are suffering diabetes. This number is estimated to reach 643 million by 2030 and 783 million by 2045. Around 6.7 million deaths were reported due to diabetes in 2021. Moreover, increase in healthcare expenditure, particularly in emerging economies, allows more patients to access advanced diabetes management technologies. As per the same source, diabetes was responsible for at least $966 billion dollars in health expenditure in 2021. Furthermore, the integration of artificial pancreas devices systems with digital health platforms and smartphone applications enhances patient engagement and allows for better remote monitoring and management, which acts as the key driving force of the market. However, high cost associated with the artificial pancreas devices systems restrains the growth of the market. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, continuous improvements in sensor technology, insulin delivery systems, and control algorithms enhance the performance and reliability of artificial pancreas systems, which are expected to offer remunerative opportunities for the expansion of the global market during the forecast period. In addition, increase in initiatives aimed at improving diabetes care and management are providing incentives for the adoption of artificial pancreas systems. For instance, the World Health Organization launched an initiative in April 2021, WHO Global Diabetes Compact. The initiative aims to reduce the risk of diabetes and ensure that diabetic individuals have access to affordable and quality treatment and care.

The artificial pancreas devices systems industry is segmented into device type, end user, and region. By device type, the market is divided into threshold suspend device systems, control-to-range (CTR) systems, and control-to-target (CTT) systems. On the basis of end user, it is divided into hospitals, clinics, homecare. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By device type, the threshold suspend device systems segment dominated the market, in terms of share, in 2023.

Depending on end user, the homecare segment captured the largest share in 2023.

Region wise, North America holds a dominant position in the market in 2023.

Competition Analysis

Competitive analysis and profiles of the major players in the global artificial pancreas devices systems market include Medtronic plc, Bigfoot Biomedical, Inc., Johnson & Johnson, Tandem Diabetes Care, Inc., Pancreum, Inc, TypeZero Technologies, LLC, Beta Bionics, Inc, Insulate Corporation, Diabeloop, and Inreda Diabetic. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data

Key Market Segments

By Device Type

Threshold Suspend Device Systems
Control-To-Range (CTR) Systems
Control-To-Target (CTT) Systems

By End User

Hospitals
Clinics
Homecare

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Medtronic plc
Bigfoot Biomedical, Inc.
Johnson & Johnson
Tandem Diabetes Care, Inc.
Pancreum, Inc
TypeZero Technologies, LLC
Beta Bionics, Inc
Insulate Corporation
Diabeloop
Inreda Diabetic

Product Code: A324367

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY DEVICE TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Device Type
4.2. Threshold Suspend Device Systems
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Control-To-Range (CTR) Systems
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Control-To-Target (CTT) Systems
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country

CHAPTER 5: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY END USER

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Clinics
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
5.4. Homecare
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country

CHAPTER 6: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY REGION

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Region
6.2. North America
- 6.2.1. Key Market Trends and Opportunities
- 6.2.2. Market Size and Forecast, By Device Type
- 6.2.3. Market Size and Forecast, By End User
- 6.2.4. Market Size and Forecast, By Country
- 6.2.5. U.S. Artificial Pancreas Devices Systems Market
  - 6.2.5.1. Market Size and Forecast, By Device Type
  - 6.2.5.2. Market Size and Forecast, By End User
- 6.2.6. Canada Artificial Pancreas Devices Systems Market
  - 6.2.6.1. Market Size and Forecast, By Device Type
  - 6.2.6.2. Market Size and Forecast, By End User
- 6.2.7. Mexico Artificial Pancreas Devices Systems Market
  - 6.2.7.1. Market Size and Forecast, By Device Type
  - 6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Device Type
- 6.3.3. Market Size and Forecast, By End User
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. Germany Artificial Pancreas Devices Systems Market
  - 6.3.5.1. Market Size and Forecast, By Device Type
  - 6.3.5.2. Market Size and Forecast, By End User
- 6.3.6. France Artificial Pancreas Devices Systems Market
  - 6.3.6.1. Market Size and Forecast, By Device Type
  - 6.3.6.2. Market Size and Forecast, By End User
- 6.3.7. UK Artificial Pancreas Devices Systems Market
  - 6.3.7.1. Market Size and Forecast, By Device Type
  - 6.3.7.2. Market Size and Forecast, By End User
- 6.3.8. Italy Artificial Pancreas Devices Systems Market
  - 6.3.8.1. Market Size and Forecast, By Device Type
  - 6.3.8.2. Market Size and Forecast, By End User
- 6.3.9. Spain Artificial Pancreas Devices Systems Market
  - 6.3.9.1. Market Size and Forecast, By Device Type
  - 6.3.9.2. Market Size and Forecast, By End User
- 6.3.10. Rest of Europe Artificial Pancreas Devices Systems Market
  - 6.3.10.1. Market Size and Forecast, By Device Type
  - 6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
- 6.4.1. Key Market Trends and Opportunities
- 6.4.2. Market Size and Forecast, By Device Type
- 6.4.3. Market Size and Forecast, By End User
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. Japan Artificial Pancreas Devices Systems Market
  - 6.4.5.1. Market Size and Forecast, By Device Type
  - 6.4.5.2. Market Size and Forecast, By End User
- 6.4.6. China Artificial Pancreas Devices Systems Market
  - 6.4.6.1. Market Size and Forecast, By Device Type
  - 6.4.6.2. Market Size and Forecast, By End User
- 6.4.7. Australia Artificial Pancreas Devices Systems Market
  - 6.4.7.1. Market Size and Forecast, By Device Type
  - 6.4.7.2. Market Size and Forecast, By End User
- 6.4.8. India Artificial Pancreas Devices Systems Market
  - 6.4.8.1. Market Size and Forecast, By Device Type
  - 6.4.8.2. Market Size and Forecast, By End User
- 6.4.9. South Korea Artificial Pancreas Devices Systems Market
  - 6.4.9.1. Market Size and Forecast, By Device Type
  - 6.4.9.2. Market Size and Forecast, By End User
- 6.4.10. Rest of Asia-Pacific Artificial Pancreas Devices Systems Market
  - 6.4.10.1. Market Size and Forecast, By Device Type
  - 6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
- 6.5.1. Key Market Trends and Opportunities
- 6.5.2. Market Size and Forecast, By Device Type
- 6.5.3. Market Size and Forecast, By End User
- 6.5.4. Market Size and Forecast, By Country
- 6.5.5. Brazil Artificial Pancreas Devices Systems Market
  - 6.5.5.1. Market Size and Forecast, By Device Type
  - 6.5.5.2. Market Size and Forecast, By End User
- 6.5.6. Saudi Arabia Artificial Pancreas Devices Systems Market
  - 6.5.6.1. Market Size and Forecast, By Device Type
  - 6.5.6.2. Market Size and Forecast, By End User
- 6.5.7. South Africa Artificial Pancreas Devices Systems Market
  - 6.5.7.1. Market Size and Forecast, By Device Type
  - 6.5.7.2. Market Size and Forecast, By End User
- 6.5.8. Rest of LAMEA Artificial Pancreas Devices Systems Market
  - 6.5.8.1. Market Size and Forecast, By Device Type
  - 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

8.1. Medtronic Plc
- 8.1.1. Company Overview
- 8.1.2. Key Executives
- 8.1.3. Company Snapshot
- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
8.2. Bigfoot Biomedical, Inc.
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Operating Business Segments
- 8.2.5. Product Portfolio
- 8.2.6. Business Performance
- 8.2.7. Key Strategic Moves and Developments
8.3. Johnson And Johnson
- 8.3.1. Company Overview
- 8.3.2. Key Executives
- 8.3.3. Company Snapshot
- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
8.4. Tandem Diabetes Care, Inc.
- 8.4.1. Company Overview
- 8.4.2. Key Executives
- 8.4.3. Company Snapshot
- 8.4.4. Operating Business Segments
- 8.4.5. Product Portfolio
- 8.4.6. Business Performance
- 8.4.7. Key Strategic Moves and Developments
8.5. Pancreum, Inc
- 8.5.1. Company Overview
- 8.5.2. Key Executives
- 8.5.3. Company Snapshot
- 8.5.4. Operating Business Segments
- 8.5.5. Product Portfolio
- 8.5.6. Business Performance
- 8.5.7. Key Strategic Moves and Developments
8.6. TypeZero Technologies, LLC
- 8.6.1. Company Overview
- 8.6.2. Key Executives
- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
8.7. Beta Bionics, Inc
- 8.7.1. Company Overview
- 8.7.2. Key Executives
- 8.7.3. Company Snapshot
- 8.7.4. Operating Business Segments
- 8.7.5. Product Portfolio
- 8.7.6. Business Performance
- 8.7.7. Key Strategic Moves and Developments
8.8. Insulate Corporation
- 8.8.1. Company Overview
- 8.8.2. Key Executives
- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
8.9. Diabeloop
- 8.9.1. Company Overview
- 8.9.2. Key Executives
- 8.9.3. Company Snapshot
- 8.9.4. Operating Business Segments
- 8.9.5. Product Portfolio
- 8.9.6. Business Performance
- 8.9.7. Key Strategic Moves and Developments
8.10. Inreda Diabetic
- 8.10.1. Company Overview
- 8.10.2. Key Executives
- 8.10.3. Company Snapshot
- 8.10.4. Operating Business Segments
- 8.10.5. Product Portfolio
- 8.10.6. Business Performance
- 8.10.7. Key Strategic Moves and Developments